Britain and America have signed a important commercial pact that will maintain zero duties on British pharmaceutical products being sold in the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these key exports will stay at nothing for a period of 36 months.
This agreement is in response to earlier threats to hike tariffs on patented pharmaceutical products, with increases mentioned up to one hundred percent.
"This agreement with the Britain bolsters the global environment for new treatments and establishes much-needed equity to American-British drug exports," a release noted.
Trade Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the US, which is clearly the largest buyer for large British pharmaceutical firms.
Trade data reveal that in the one-year period to the end of September, the UK shipped pharmaceutical products worth billions to the US. This amount represented 17.4% of all goods exports in that period.
"This deal protects employment, stimulates capital expenditure and sets the stage for the UK to become a global hub for medical research," a minister stated.
Key UK Commitments
The deal includes several key changes from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to raise total NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, rebates topped 20%.
Recent Tensions
The deal follows a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
This friction were intensified by assertions that US customers were charged several times more for the same drugs than people in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been paused or cancelled, while substantial expansions have been pledged toward US facilities.
The Science Minister stated that the NHS must invest a greater share on medicines, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
